Neurocrine Biosciences (NBIX) EBITDA Margin (2010 - 2026)

Neurocrine Biosciences has reported EBITDA Margin for 16 years, with the latest figure at 22.74% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 2080.0% year-over-year to 22.74%; the trailing twelve-month figure through Mar 2026 stood at 21.27% (up 836.0% YoY), and the FY2025 full-year result was 16.99%, up 255.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 22.74%, up from 19.07% in the prior quarter.
• The five-year high for EBITDA Margin was 30.36% in Q4 2023, with the low at 99.0% in Q2 2022.
• Historically, EBITDA Margin has averaged 8.08% across 5 years, with a median of 16.54% in 2023.
• Annual changes were most pronounced in 2022 — EBITDA Margin sank 11354 bps — and 2023, when it surged 12045 bps.
• Neurocrine Biosciences' EBITDA Margin stood at 23.08% in 2022, then surged by 32 bps to 30.36% in 2023, then sank by 50 bps to 15.04% in 2024, then increased by 27 bps to 19.07% in 2025, then rose by 19 bps to 22.74% in 2026.
• The last three EBITDA Margin figures came in at 22.74% (Q1 2026), 19.07% (Q4 2025), and 26.44% (Q3 2025), per Business Quant data.